Symptom Status and Quality of Life Following Prostatectomy

Fowler, Floyd J.; Wennberg, John E.; Timothy, R.; Barry, Michael J.; Mulley, Albert G.; Hanley, D.A.

doi:10.1016/s0022-5347(17)40642-2

Cited by 42 publications

(66 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the same way, symptom reduction and HRQL improvement were sustained up to 36 months (748% and 43%, respectively); interestingly the storage score was signi®-cantly more reduced than voiding score, and it had been shown that the former was perceived by the patients as the most bothersome 12 and correlated more with HRQL changes. 38 Physical/functional dimension improved more than social life status and mental dimensions, which contrasts with ®ndings of Fowler and coworkers 39 and of Doll and colleagues 40 in patients who underwent surgery (prostatectomy and transurethral resection of prostate, respectively). These data con®rm the importance of disease-speci®c HRQL measurements, which are better able than generic instruments to detect changes due to treatment.…”

Section: Discussionmentioning

confidence: 81%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objectives: To investigate (a) the magnitude and durability of symptom score reduction and HRQL score improvement (including sexual drive); (b) adverse outcomes; and (c) progression to acute urinary retention and prostate surgery up to three years of treatment with alfuzosin.Methods: Three thousand two hundred and twenty-eight BPH-patients out of 812 centers were included in a prospective three-year open-labelled study and treated with alfuzosin (immediate release formulation) at the recommended dosage. A symptom score (Boyarsky modi®ed) and a 20-item BPH speci®c HRQL score including three questions of sexuality (Urolife TM BPH QoL 20) were selfadministered at baseline, 3,6,12,18,24,30, and 36 months.Results: Two thousand ®ve hundred and seventy-nine patients (79.9%) completed the study at the end of three years. Symptom score was signi®cantly reduced by 54% at 3 months and this reduction was maintained up to 36 months (748.4%); HRQL score was signi®cantly improved by 45.4% at 12 months and this improvement was maintained up to 36 months ( 43.4%). Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events was similar to that previously observed in placebo-controlled studies (vertigo/dizziness: 2.1%). Adverse events accounted for 4.2% of the drop-outs. 120 patients (3.7%) were operated on for BPH and nine patients (0.3%) experienced acute urinary retention.Conclusion: This medical outcomes study con®rms the long-term safety pro®le of alfuzosin in the naturalistic conditions of general practice and highlights the need to measure HRQL in the context of patient's preferences.

show abstract

Section: Discussionmentioning

confidence: 81%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…There are several important differences in how the instrument [5], the Danish symptom score (DAN-PSS-1) questionnaires are completed among the scoring systems. [6], the AUA symptom score [7], the I-PSS (which The Boyarsky [3] and Madsen-Iversen [4] questionnaires is advocated for use by the WHO International were designed to be completed by clinicians.…”

Section: [4] the Maine Medical Assessment Program (Mmap)mentioning

confidence: 99%

“…[6], the AUA symptom score [7], the I-PSS (which The Boyarsky [3] and Madsen-Iversen [4] questionnaires is advocated for use by the WHO International were designed to be completed by clinicians. The MMAP Consultation on BPH [8] and an adapted version of the instrument [5], DAN-PSS-1 [6], AUA symptom score [7], Boyarsky schedule, the Bolognese instrument [9].…”

Section: [4] the Maine Medical Assessment Program (Mmap)mentioning

confidence: 99%

The ICS–‘BPH’ Study: the psychometric validity and reliability of the ICSmale questionnaire

Donovan

Abrams

Peters

et al. 1996

British Journal of Urology

268

179

View full text Add to dashboard Cite

“…-Ethical objections [14,36]. -There may be possible political obstacles if those who fund and manage health services do not want their policies studied [11].…”

Section: Impossibilitymentioning

confidence: 99%

The rationale for a spine registry

2005

View full text Add to dashboard Cite

IntroductionOrthopaedic registers are increasingly established in all parts of the world and the large majority are used for collection of data from total joint arthroplasties [5,17,18,21,26,27].The Swedish Hip Register still serves as the best example for a well organised and functioning arthroplasty register. On the background of the Scandinavian experience with implementation and organisation of orthopaedic registries, the first reports of a national spine register also came from the northern parts of Europe [33]. The Swedish lumbar spine registry is not only the first but also the only national spine register that has reported its methodology and is continuously reporting its results in the peer-reviewed literature. Four key factors contribute to the success of the Swedish endeavour: A national health service and existing unique patient identifiers make possible the identification and follow-up of 'migrating' patients who C. Ro¨der U. Mu¨ller M. Aebi

show abstract

Symptom Status and Quality of Life Following Prostatectomy

Cited by 42 publications

References 0 publications

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

The ICS–‘BPH’ Study: the psychometric validity and reliability of the ICSmale questionnaire

The rationale for a spine registry

Contact Info

Product

Resources

About